Epithalon
ProtocolProtocol design for Epithalon starts with pharmacokinetics and ends with calendar planning. The compound's Very short (minutes) half-life via subq/intranasal administration places it in the multi-daily-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.
Key Takeaways
Scheduling lens: Epithalon's Very short (minutes) half-life via subq/intranasal places it in the multi-daily-dosing bucket. Mechanism: Identified by Khavinson in St. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Identified by Khavinson in St. Petersburg. Stimulates telomerase activity in somatic cells, with downstream effects on telomere length over multi-year cycles. Normalises age-related decline in pineal melatonin output. Putative epigenetic effects on aging-clock methylation patterns are an active area of investigation. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Epithalon.
Cycle length and off-cycle planning
Standard Epithalon cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Daily and weekly timing
Epithalon with a Very short (minutes) half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily for 10-20 day cycles, 1-2x yearly, with consistency mattering more than the absolute clock time of any single dose.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Epithalon protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Epithalon schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
For pulse strategies scheduling, Epithalon is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for Epithalon in cycle design starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for Epithalon in weekly timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For off-time scheduling, Epithalon is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 5-10 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 3-10 mg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 5-10 mg | 1x daily for 10-20 day cycles, 1-2x yearly |
| Maintenance phase | SubQ | 4-10 mg | Ongoing with periodic pauses |
Dose timing for Epithalon is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Epithalon stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- Epithalon + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Epithalon's mechanism in protocol / scheduling / cycling protocols.
- Epithalon + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Epithalon's mechanism in protocol / scheduling / cycling protocols.
- Epithalon + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Epithalon's mechanism in protocol / scheduling / cycling protocols.
- Epithalon + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Epithalon's mechanism in protocol / scheduling / cycling protocols.
Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard.
Lens-specific safety considerations for protocol / scheduling / cycling use of Epithalon: Outstanding safety profile in human studies extending to 15-year follow-up. No reported serious adverse events. Cycle-based dosing is standard. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Epithalon | Pineal-derived tetrapeptide | Very short (minutes) | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Daily timing for Epithalon?
What if I miss a dose?
Can I shift my schedule with travel?
When to integrate Epithalon into an existing stack?
What is Epithalon?
What does Epithalon stack well with?
Start a Epithalon Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified Epithalon and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 390 Da
- Sequence length
- 4 aa
- Half-life
- Very short (minutes)
- WADA
- Not specifically listed
- FDA
- Unapproved
- Research
- Multi-decade Russian research; long-running human cohort studies
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Epithalon unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for Epithalon
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised